News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …
Orchestra BioMed Holdings, Inc. (OBIO) recently reported Q2 results showing revenues significantly below expectations, though statutory losses were in line with forecasts. Analysts have since updated their models, projecting a substantial 99% reduction in 2026 revenues and an increase in per-share losses, indicating a …
Orchid Island Capital (NYSE:ORC) has declared a monthly dividend of $0.10 per share, payable on September 29th to shareholders of record on August 31st, resulting in an annualized yield of approximately 18.1%. Despite the high yield, the dividend appears financially strained with a 151.9% …
Orchid Island Capital, Inc. (NYSE: ORC) has declared a monthly cash dividend of $0.10 per share for August 2026. This dividend will be paid on September 29, 2026, to shareholders of record as of August 31, 2026, with an ex-dividend date also on August …
The article reports on an 8K filing by Orchid Island Capital (ORC) for August 12. It is a brief announcement from Investing.com, typical of their automatic news updates regarding SEC filings. The content primarily consists of the headline and a single line indicating the …
Orchid Island Capital (NYSE: ORC) declared a $0.10 monthly cash dividend for August 2026 and reported its July 31, 2026, RMBS portfolio characteristics. The company held $11.26 billion in Agency RMBS mortgage assets, primarily pass-through securities, and detailed its repurchase borrowings and hedge positions. …
The article analyzes Orchid Island Capital Inc. (NYSE: ORC) highlighting divergent sentiment readings across horizons and an exceptional 21.5:1 risk-reward setup. It outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis indicating support …
Orchestra BioMed (NASDAQ:OBIO) reported a quarterly loss of $0.38 per share, missing analyst estimates by $0.03. Despite the earnings miss and negative financial metrics, the company's shares increased by 5.2% and insiders purchased a significant amount of stock. Analyst sentiment is mixed but generally …
Orchestra Biomed Holdings (NASDAQ: OBIO) reported second-quarter EPS of $-0.380
The average 12-month price target for Orchestra BioMed Holdings, Inc. (OBIO) stock has increased to $12.33, up from $12.17, according to estimates from six analysts. This new target suggests a potential upside of approximately 177% from its closing price on August 10. The consensus …
Orchestra BioMed announced its second-quarter 2026 financial results, highlighting progress in its two cardiovascular programs: AVIM Therapy and Virtue SAB. The company reported that its BACKBEAT trial for AVIM Therapy is on track to meet its target enrollment by Q3 2026, with primary data …
Orchestra BioMed Holdings reported a net loss of $24.1 million in Q2 2026, widening from the previous year, despite an 89% drop in revenue to $88,000. The loss was primarily due to increased research and development expenses for pivotal clinical trials. However, the company …
Orchestra BioMed reported its Q2 2026 financial results, including a net loss of $24.1 million, and provided updates on its pivotal clinical trials. The BACKBEAT Trial for uncontrolled hypertension is on track to enroll 284 patients by Q3 2026, with primary results expected in …
Orchestra BioMed Holdings, Inc. (OBIO) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.35 loss, though it was an improvement from a $0.5 loss a year ago. The company also missed revenue estimates, posting $0.09 million against …
Dorchester Minerals, L.P. reported significant earnings growth in the first half of 2026, with revenue rising to US$114.95 million and net income to US$58.09 million. Alongside this, the partnership expanded its footprint by acquiring approximately 3,100 net royalty acres in North Dakota’s Williston Basin. …
Dorchester Minerals, L.P., an oil and gas royalty company, is facing challenges due to falling oil prices but presents an attractive investment opportunity. A recent acquisition in the Williston Basin diversifies revenue, and the stock trades at a 39% discount to its long-term price-to-free-cash-flow …
This article provides an AI-driven analysis for Dorchester Minerals L.p. (NASDAQ: DMLP), highlighting a weak near and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, based on a 30.6:1 risk-reward setup. The analysis also …
Dorchester Minerals (DMLP) reported strong Q2 and H1 results in 2026, leading to increased revenue and earnings per share. Despite an 18.7x P/E ratio, which is higher than industry averages, Simply Wall St's DCF model suggests a fair value of $65.98 against its current …
Search by ticker symbol or company name and select a result to open its chart.